{"organizations": [], "uuid": "6e2cbaca475206f02651e1a03114181eddbf0245", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-egalet-says-received-notice-from-t/brief-egalet-says-received-notice-from-teva-pharmaceuticals-usa-of-anda-submission-for-approval-to-market-generic-version-of-arymo-er-extended-release-tablets-idUSFWN1QD1HO", "country": "US", "domain_rank": 408, "title": "BRIEF-Egalet Says Received Notice From Teva Pharmaceuticals USA Of ANDA Submission For Approval To Market Generic Version Of Arymo ER Extended-Release Tablets", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-24T00:39:00.000+02:00", "replies_count": 0, "uuid": "6e2cbaca475206f02651e1a03114181eddbf0245"}, "author": "", "url": "https://www.reuters.com/article/brief-egalet-says-received-notice-from-t/brief-egalet-says-received-notice-from-teva-pharmaceuticals-usa-of-anda-submission-for-approval-to-market-generic-version-of-arymo-er-extended-release-tablets-idUSFWN1QD1HO", "ord_in_thread": 0, "title": "BRIEF-Egalet Says Received Notice From Teva Pharmaceuticals USA Of ANDA Submission For Approval To Market Generic Version Of Arymo ER Extended-Release Tablets", "locations": [], "entities": {"persons": [{"name": "teva pharmaceutica", "sentiment": "neutral"}], "locations": [], "organizations": [{"name": "brief-egalet says received notice from teva pharmaceuticals usa of anda", "sentiment": "neutral"}, {"name": "sec", "sentiment": "none"}, {"name": "egalet corp", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "teva", "sentiment": "none"}, {"name": "teva pharmaceuticals usa of anda", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 23 (Reuters) - Egalet Corp:\n* EGALET - CO, UNIT RECEIVED NOTICE FROM TEVA PHARMACEUTICALS USA OF ANDA SUBMISSION FOR APPROVAL TO MARKET GENERIC VERSION OF ARYMO ER EXTENDED-RELEASE TABLETS\n* EGALET SAYS CURRENTLY REVIEWING DETAILS OF TEVAâ€™S NOTICE, PARAGRAPH IV CERTIFICATION - SEC FILING Source text: ( bit.ly/2FqX1Lp ) Further company coverage:\n ", "external_links": [], "published": "2018-02-24T00:39:00.000+02:00", "crawled": "2018-02-24T00:54:53.002+02:00", "highlightTitle": ""}